Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis.
Aadya NagpalRichard P RedversXiawei LingScott AytonMiriam FuentesElnaz TavanchehIrmina DialaAlshad LalaniSherene LoiSteven DavidRobin L AndersonYvonne SmithDelphine MerinoDelphine DenoyerNormand PouliotPublished in: Breast cancer research : BCR (2019)
The TBCP-1 model recapitulates the spontaneous spread of HER2-positive breast cancer to the brain seen in patients and provides a unique tool to identify novel therapeutics and biomarkers. Neratinib-induced ferroptosis provides new opportunities for therapeutic intervention. Further evaluation of neratinib neoadjuvant therapy is warranted.
Keyphrases
- positive breast cancer
- rectal cancer
- end stage renal disease
- cell death
- locally advanced
- white matter
- lymph node
- resting state
- chronic kidney disease
- newly diagnosed
- randomized controlled trial
- peritoneal dialysis
- prognostic factors
- squamous cell carcinoma
- small molecule
- high glucose
- functional connectivity
- diabetic rats
- stem cells
- oxidative stress
- blood brain barrier
- stress induced
- subarachnoid hemorrhage
- replacement therapy